LN:SUMM Summit Therapeutics

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol SMMT.

20.50 GBP
As of 02/21/2020


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Other
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  01/01/1900
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   32,901,476 GBP
Current dividend yield:   0.00%
CUSIP:    
ISIN:        GB00BN40HZ01
Sedol:      

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy